EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR  by Wu, Shang-Gin et al.
ORIGINAL ARTICLE
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Introduction: The echinoderm microtubule-associated protein like
4-anaplastic lymphoma kinase (EML4-ALK) fusion represents a
novel target in a subset of non-small cell lung cancer, especially
adenocarcinoma. EML4-ALK fusion is mutually exclusive with
epidermal growth factor receptor (EGFR) mutations. To understand
the impact of EML4-ALK on the prognosis of non-small cell lung
cancer, we examined EML4-ALK fusion in lung adenocarcinoma
from patients with wild-type EGFR and analyzed their clinical
treatment outcomes.
Methods: Lung adenocarcinoma patients with malignant pleural
effusions having wild-type EGFR and measurable target lesions
were enrolled for EML4-ALK analysis by reverse transcription-
polymerase chain reaction and direct sequencing. Demographic
data, EML4-ALK status, and survival data were analyzed. We also
performed fluorescence in situ hybridization on some available
tumor samples to validate the PCR result. In addition, K-ras muta-
tion was analyzed for patients without EML4-ALK fusion genes.
Results: A total of 116 patients with wild-type EGFR sequencing
results had complete clinical data for analysis. No patients received
ALK inhibitor therapy. There were 39 patients (34%) with the
EML4-ALK fusion gene. The concordance rate between reverse
transcription-polymerase chain reaction and fluorescence in situ
hybridization was 85%. The K-ras mutation rate for patients without
EML4-ALK fusion gene was 6.5%. By multivariate analysis, patients
who had better performance status (p  0.001) and EML4-ALK
translocation (p  0.017) had longer overall survival. Comparing
patients with tumors harboring variant 1 with those harboring
nonvariant 1 EML4-ALK fusion genes, there were no significant
differences in clinical factors and survival outcome.
Conclusion: For lung adenocarcinoma patients with wild-type
EGFR, EML4-ALK translocation is associated with longer overall
survival.
Key Words: EML4-ALK, EGFR mutation, Lung cancer, Adeno-
carcinoma.
(J Thorac Oncol. 2012;7: 98–104)
Personalized cancer therapy has attracted much attentionbecause more and more oncologic molecules have been
researched and specific molecular target treatment strategies
have been developed. A subset of non-small cell lung cancer
(NSCLC) patients with epidermal growth factor receptor
(EGFR) mutation has a higher response rate with EGFR
tyrosine kinase inhibitors (TKIs).1
In 2007, Soda et al.2 identified a fusion gene of the
anaplastic lymphoma kinase (ALK) with the echinoderm
microtubule-associated protein like 4 (EML4) in NSCLC.
EML4-ALK is most often detected in never-smoker or light
smoker lung adenocarcinoma patients.2–6 In the Asian popu-
lation, the EML4-ALK fusion is detected in 3 to 5% of lung
adenocarcinomas2,6,7 and is also associated with a variety of
histological features in lung adenocarcinoma, including aci-
nar pattern, signet-ring cell, and papillary with bronchioloal-
veolar components.4,6,8–10 In addition, EML4-ALK occurs in
mutual exclusion to Kirsten rat sarcoma viral oncogene ho-
molog (K-ras) and EGFR mutations.2,4,5,11,12
Crizotinib (PF-02341066) is a dualMET/ALK TKI. In a
phase I trial, EML4-ALK-positive patients with advanced
lung cancer given crizotinib showed favorable treatment
response.13,14 After the phase I dose escalation study, Kwak et
al.13 identified 82 patients with advanced ALK-positive dis-
ease from 1500 NSCLC patients for crizotinib treatment. The
response rate was 57% (47 of 82), and 27 patients (33%) had
stable disease. The high response rate and a good safety
profile among patients harboring the EML4-ALK fusion gene
have led to the initiation of the phase III clinical trials.
Prior studies have mostly focused on the analysis of
surgical excision specimens from patients with early stage
NSCLC, but there are few reports for NSCLC patients with
advanced stage diseases.2,3,6,9,11,15 In addition, few studies
have reported the survival outcome of lung cancer patients
with tumors harboring EML4-ALK translocation but without
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crizotinib treatment, and patient numbers in previous studies
are relatively small.4,15,16
To understand the impact of EML4-ALK on clinical
treatment outcome of advanced lung adenocarcinoma with
wild-type EGFR, we examined EML4-ALK fusion gene in
malignant pleural effusions from lung adenocarcinoma pa-
tients with wild-type EGFR and analyzed their clinical treat-
ment outcomes.
MATERIALS AND METHODS
Patients and Tissue Procurement
We prospectively collected pleural fluid samples from
consecutive patients who received thoracentesis in the chest
ultrasonography examination room of the National Taiwan
University Hospital from June 2005 to December 2009. All
patients had signed an informed consent for future molecular
analyses before thoracentesis was performed. Malignant
pleural effusions were confirmed by cytology examination.
Some of the samples were previously examined and reported
in studies of EGFR mutations.17–20 This study was approved
by the Institutional Review Board of National Taiwan Uni-
versity Hospital Research Ethics Committee (Institutional
Review Board approval number: 993703238).
The World Health Organization pathology classifica-
tion was used to define lung cancer histology.21 All lung
cancer patients received complete lung cancer staging
work-up according to our routine practice, which included
computed tomography (CT) of the head, chest, and abdomen
and whole body bone scintigraphy.22 Only patients with
measurable tumors on CT were included in this study. We
only enrolled lung adenocarcinoma patients with wild-type
EGFR for EML4-ALK analysis.
Clinical data including demographic information and
smoking status were recorded, and imaging studies were
collected. Patients who had smoked less than 100 cigarettes
in their lifetime were categorized as nonsmokers. Those who
had smoked 10 or less pack-years were categorized as light
smokers.4 The rest were categorized as heavy smokers. The
cancer stages and Eastern Cooperative Oncology Group per-
formance status (ECOG PS) were also recorded.22,23 The date
of diagnosis, all systemic treatments, including chemotherapy
and EGFR TKIs, and responsiveness to the treatment were
recorded. No patients received crizotinib therapy.
Response Evaluation of Lung
Adenocarcinoma Patients
Systemic chemotherapy included chemotherapy and
EGFR TKIs, erlotinib (150 mg/d) (Tarceva; OSI Pharmaceu-
ticals, Inc., Melville, NY) or gefitinib (250 mg/d) (Iressa;
AstraZeneca, Wilmington, DE). EGFR TKI was taken as a
single agent every day. No concurrent chemotherapy or
radiotherapy for the lung tumors was performed during
EGFR TKI therapy.
Chest radiography every 2 to 4 weeks and a chest CT
scan (including the liver and adrenal glands) every 2 to 3
months were performed as routine clinical practice and as
needed to monitor the response and progression of the dis-
ease. The “Response Evaluation Criteria in Solid Tumors
(RECIST) guidelines (version 1.1)” unidimensional method
was adopted to evaluate the measurable solid tumors.24 Over-
all survival was defined as the period from the date of
first-line systemic treatment to the date of death.
Collection of Pleural Effusion Fluid
Pleural effusion was collected into heparinized tubes. A
10 ml sample of the fluid was centrifuged at 250g for 10
minutes at 4°C, and the cell pellets were frozen. RNA was
extracted from cell lysate with a Qiamp RNA Mini Kit
(Qiagen) according to the manufacturer’s instructions. Total
RNA was extracted using Tri-reagent (Molecular Research
Center, Inc., Cincinnati, OH) and stored at 80°C until use.
Sequencing of EGFR Exons 18–21 and K-ras
Exons 2 and 3
We amplified exons 18–21 of EGFR by reverse tran-
scription polymerase chain reaction (RT-PCR) with Qiagen
OneStep RT-PCR Kit (Qiagen, Hilden, Germany). The con-
ditions of RT-PCR have been described previously.25
The exons 2–3 of K-ras gene was amplified by RT-PCR
using the following primers: forward, 5-GGCCTGCT-
GAAAATGACTGA-3 and 5-TCTTGCTAAGTCCTGAGC-
CTGTT-3. The K-ras reference sequence is based on
NM_004985 from the National Center for Biotechnology
Information database.
PCR amplicons were sequenced with ABI PRISM 3100
(Applied Biosystems, Foster City, CA) in both sense and
antisense directions. The specimens with mutations were
confirmed in two rounds. Only specimens with the same
results identified in both rounds were recorded as mutation-
positive. Mutations were also checked against SNP database.
Detection of EML4-ALK Fusion Gene
After identification of malignant pleural effusion with
wild-type EGFR, reverse transcription of the extracted RNA
was performed to generate complementary DNA (cDNA) ac-
cording to the previous published method.15,17 PCR was per-
formed to screen for EML4-ALK fusion cDNAs. The primer sets
and PCR conditions were adapted from Takahashi et al.15
RT-PCR was performed using HotStar TaqMaster Mix
Kits (Qiagen). The RT-PCR primer set used was as in prior
reports: 5-GTGCAGTGTTTAGCATTCTTGGGG-3 (for-
ward primer, on exon 13 of EML4) and 5-TCTTGCCAG-
CAAAGCAGTAGTTGG-3 (reverse primer, on exon 21 of
ALK).2,3,10 The other primer was used to detect other types of
fusion transcripts consisting of the upper exons of EML4 and
ALK: 5-GTCAGCTCTTGAGTCACGAGTT-3 (forward
primer, on exon 2 of EML4) and 5-TCTTGCCAG-
CAAAGCAGTAGTTGG-3 (reverse primer, on exon 21 of
ALK). The RT-PCR conditions used was as described by
Takahashi et al.15
RT-PCR amplicons were purified and sequenced using
the Big Dye Terminator sequencing kit (Applied Biosystems)
according to the manufacturer’s instructions. The different
variants were confirmed according to previously published
reports.15,26 The most common variants of EML4-ALK fusion
gene were variant 1 with exon 13 of EML4, variant 2 with
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exon 20 of EML4, and variant 3a/b with exon 6a/b of EML4
fused to exon 20 of ALK, respectively.
Fluorescence In Situ Hybridization
We prepared 4-m paraffin-embedded histological sec-
tions for fluorescence in situ hybridization (FISH) analysis.
To assess the rearrangement of ALK, commercial Vysis LSI
ALK Dual Color, Break Apart Rearrangement Probe (2p23)
(Abbott Molecular Inc., Des Plaines, IL) was used according
to the manufacturer’s instructions (Vysis). Briefly, the paraf-
fin-embedded tissue section slides were deparaffinized in
xylene (three times, 10 minutes each), followed by two
5-minute washes in 100% ethanol. The sections were treated
with pretreatment reagent (Abbott Molecular) at 80°C for 10
minutes, then the sample was allowed to react with protease
mixed with a protease buffer. The LSI ALK dual-color probe
was used to hybridize the 2p23 band with SpectrumOrange
(red) on the telomeric side of the ALK breakpoint and Spec-
trumGreen on centromeric side of the ALK gene breakpoint
(Abbott Molecular).
Results were analyzed in a fluorescent microscope
(Zeiss AXIO Imager.A1) using the Axio Vision Release 4.5
software. A minimum of 100 nuclei was scored. A FISH-
positive case was defined as having more than 15% tumor
cells showing separated green and red signals or single red
signals identified cells with rearranged ALK. FISH was per-
formed and analyzed by the Pathologist (Y.L.C.) who did not
know the EML4-ALK RT-PCR results.
Statistical Analysis
All categorical variables were analyzed with Pearson’s 2
tests, except where a small size (less than five) required the use
of Fisher’s exact test. The overall survival were plotted by the
Kaplan–Meier method and compared by the log-rank test. Mul-
tivariate analysis for overall survival was performed using the
Cox’s proportional hazards model. Two-sided p values less than
0.05 were considered significant. All analyses were performed
using SPSS version 17.0 (SPSS Inc., Chicago, IL).
RESULTS
Clinical Characteristics
A total of 1066 pleural effusions were collected from
743 patients in the chest ultrasonography examination room
of the National Taiwan University Hospital during June 2005
to December 2009. There were 650 malignant pleural effu-
sions, which included 588 lung adenocarcinomas, 8 lung
squamous cell carcinomas, 7 not otherwise specified NSCLC,
20 small cell lung cancers, and 27 malignancies other than
lung cancers. Of the 588 malignant pleural effusions of lung
adenocarcinoma, RNA from 14 samples was not sufficient for
RT-PCR and sequencing. The RT-PCR and EGFR mutation
sequencing success rate was 97.6% (574 of 588).
The 574 malignant pleural effusions of lung adenocar-
cinoma came from 386 patients. Of these, 142 patients
harbored wild-type EGFR and 244 patients harbored EGFR
mutations. Among the 142 patients with wild-type EGFR,
116 had measurable tumors on CT and sufficient samples for
EML4-ALK fusion gene detection and sequencing. These 116
patients were included in this study.
There were 62 males (53%) and 54 females (47%). The
median age at which lung cancer was diagnosed was 66.0
years (range, 27.9–91.1 years), with 81 non-/light smokers
(70%) and 35 heavy smokers (30%). All patients had malig-
nant pleural effusions and were classified as having stage IV
disease.22 Other clinical characteristics of these patients are
shown in Table 1.
EML4-ALK Fusion Gene Status
Of the 116 patients with tumors harboring wild-type
EGFR, 39 patients (34%) harbored the EML4-ALK fusion
gene. The median age between those with and without EML4-
ALK fusion gene were not statistically significantly different
(66.1 versus 65.9 years; p  0.593, by Mann-Whitney U
test). EML4-ALK gene presence did not differ by gender
(female versus male, 37.0% versus 30.6%; p  0.467) or
smoking history (non-/light smoker versus heavy smoker,
35.8% versus 28.6%; p  0.449) (Table 1).
TABLE 1. Characteristics and EML4-ALK Status of Lung Adenocarcinoma Patients with Wild-Type EGFR
Variable No. of Patients EML4-ALK() EML4-ALK() p
Total (N) 116 39 77
Age, median (range) 66.0 (27.9–91.1) 66.1 (27.9–86.7) 65.9 (28.8–91.1) 0.593a
Sex
Female 54 20 (51.3%) 34 (44.2%) 0.467
Male 62 19 (48.7%) 43 (55.8%)
Smoking
Non-/light smoker 81 29 (74.4%) 52 (67.5%) 0.449
Heavy smoker 35 10 (25.6%) 25 (32.5%)
ECOG PS
0–1 99 32 (82.1%) 67 (87.0%) 0.475
2–4 17 7 (17.9%) 10 (13.0%)
a By Mann-Whitney U test.
ECOG PS, Eastern Cooperative Oncology Group performance status.
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ALK FISH Results
Among the 39 patients with EML4-ALK fusion detected
by RT-PCR, 12 patients had adequate paraffin-embedded
tumor tissues obtained from surgical resection or biopsy
available for FISH assessment. Of these, none of them was
pleural effusion cell block. 10 (83%) had tumors with positive
ALK FISH. Furthermore, from eight patients who had adequate
tumor samples for ALK FISH but whose malignant pleural
effusion did not have EML4-ALK fusion genes by RT-PCR, we
found seven (87.5%) with negative ALK FISH. The concordance
rate between FISH and RT-PCR results was 85% (17 of 20)
(Supplemental Table 2, http://links.lww.com/JTO/A194).
K-ras Mutation Status
Because EGFR mutation, K-ras mutation, and ALK
alterations are mutually exclusive in lung adenocarcinoma,12
K-ras analysis was performed for the 77 patients without
EML4-ALK fusion gene. There were five patients harboring
tumors with K-ras mutations (Supplemental Table 3, http://
links.lww.com/JTO/A194). The K-ras mutation rate was
6.5% of the EGFR wild type and EML4-ALK wild type
patients. Two were heavy smokers and 3 were nonsmokers.
The K-ras mutation rates were not different between heavy
smokers (8%, 2 of 25) and non-/light smokers (6%, 3 of 52;
p  0.710).
Treatments and Overall Survival
The median follow-up duration of the 116 patients was
31.7 months at the time of review among the 30 patients
(26%) still alive and the 86 patients (74%) had died at that
time. The median overall survival was 11.6 months.
There were no significant treatment differences be-
tween patients with and without EML4-ALK fusion genes
(Supplemental Table 1, http://links.lww.com/JTO/A194).
Twenty-five of 37 patients with EML4-ALK fusion gene and
42 of 77 patients without EML4-ALK fusion gene received
platinum-based doublet chemotherapy (64.1% versus 54.5%;
p  0.325). Thirty-two patients with EML4-ALK fusion gene
and 54 without EML4-ALK fusion gene received second- or
subsequent-line therapy (82.1% versus 70.1%; p 0.166). In
addition, 21 patients with EML4-ALK fusion gene and 29
patients without EML4-ALK fusion genes received pem-
etrexed treatment (53.8% versus 37.7%; p  0.096). There
was no difference in the use of EGFR TKI (82.1% versus
64.9%; p  0.056). The timing of EGFR TKI treatment in
both groups was also not different (p 0.800) (Supplemental
Table 1, http://links.lww.com/JTO/A194).
The difference between overall survival was statisti-
cally significant between patients with and without the
EML4-ALK fusion genes (median, 14.7 versus 10.3 months;
p 0.009) (Figure 1). In addition, univariate analysis showed
that patients with ECOG PS 0–1 (13.8 versus 1.4 months;
p  0.001) had longer overall survival (Table 2). Although
the patients who received EGFR TKIs had longer overall
survival than those without EGFR TKI treatment (13.8 versus
8.4 months), the difference did not reach statistical signifi-
cance (p  0.055).
There was no significant difference in overall survival
between heavy smokers and non-/light smokers (12.3 versus
11.6 months; p  0.488). To clarify the interaction in overall
survival between smoking and EML4-ALK fusion gene, we
divided the patients to heavy smokers and non-/light smokers.
Each group was further stratified by EML4-ALK fusion gene.
For the heavy smoker patients, there was no statistical sig-
nificant difference in overall survival (EML4-ALK () 12.3
months versus EML4-ALK () 8.6 months; p  0.782). For
the non-/light smoker patients, the difference in overall sur-
vival was statistically significant (EML4-ALK () 16.8
months versus EML4-ALK () 10.3 months; p  0.005)
(Supplemental Figures 1a and b http://links.lww.com/JTO/
A192http://links.lww.com/JTO/A193).
Cox regression model showed that presence of EML4-
ALK fusion gene (hazard ratio [HR], 0.53; 95% confidence
interval, 0.32–0.87; p  0.011) and having ECOG PS 2–4
(HR, 5.88; 95% confidence interval, 2.98–11.58; p  0.001)
statistically significantly affect overall survival (Table 2).
Differences Between Variant 1 and Nonvariant
1 of EML4-ALK Fusion Gene
Of the 39 patients with EML4-ALK fusion gene, 24 had
variant 1 and 15 with nonvariant 1 genes (two variant 2, six
variant 3a, five variant 3b, and two other variant types). The
median age between variant 1 and nonvariant 1 patients were
not statistically significantly different (median: 68.8 versus
57.8 years; p  0.279, by Mann-Whitney U test). There were
no significant differences by gender (p  0.129) and ECOG
PS (p  0.216, by Fisher exact test) between patients with
variant 1 and nonvariant 1 EML4-ALK fusion genes. Com-
pared with nonvariant 1 patients, patients with variant 1
EML4-ALK were more likely to be heavy smokers (37.5%, 9
of 24, versus 7.1%, 1 of 15; p 0.057, by Fisher’s exact test)
(Table 3).
FIGURE 1. Kaplan–Meier survival curve of overall survival of
lung adenocarcinoma patients with EML4-ALK (solid line)
and without EML4-ALK fusion gene (dashed); the difference
was statistically significant (median, 14.7 versus 10.3
months; p  0.009, by the log-rank test).
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For overall survival, the patients with variant 1 EML4-
ALK fusion gene did not survive longer than those with
nonvariant 1 (14.1 versus 16.8 months; p  0.869).
DISCUSSION
For lung adenocarcinoma patients with wild-type
EGFR, this study adds to the body of knowledge that EML4-
ALK is a favorable factor for overall survival. In addition,
there were no significant differences in clinical factors and
survival outcome between patients with tumors harboring
variant 1 and those harboring nonvariant 1 EML4-ALK fusion
gene. This may move us toward understanding the full impact
of EML4-ALK on NSCLC.
In the IPASS study, the PFS of gefitinib in patients with
wild-type EGFR tumors is 1.5 months.1 Other reports showed
the overall survival in lung adenocarcinoma patients with
wild-type EGFR as 12 to 14 months.27,28 This study shows
that EGFR TKI-treated lung adenocarcinoma patients with
wild-type EGFR had 1.3 months of PFS and 13.2 months of
overall survival, which is consistent with prior reports.1,27,28
Shaw et al.4 reported that the median survival was 20
months in patients harboring the EML4-ALK fusion gene and
16 months in patients without both the EGFR mutation and
EML4-ALK fusion gene. The difference was not statistically
significant. This study showed that there is a significant
difference in the overall survival between patients with and
without the EML4-ALK fusion gene (HR, 0.53; p  0.011).
Compared with the study by Shaw et al.,4 this study enrolled
more patients, especially those with the EML4-ALK fusion
genes. In addition, the present cohort study enrolled patients
with advanced diseases and had longer median follow-up
duration (31.7 months). EML4-ALK may have important
implications in overall survival of EGFR wild-type lung
adenocarcinoma. Prospective clinical trials are necessary to
confirm this finding.
In this study, the K-ras mutation rate in EML4-ALK
negative patients was only 6.5% and cannot explain the poor
survival of these patients. The result was similar to the other
countries in Eastern Asia, where the frequency of K-ras
mutation has been reported as less than 10%.29–31 The K-ras
mutation rates of heavy smoker lung adenocarcinoma patients
was 8%, which is consistent with the result of the study by
Wu et al.29 done in Taiwan. In addition, there was no
TABLE 2. Multivariate Analysis of Prognostic Factors for Overall Survival of Adenocarcinoma Patients with Wild-Type EGFR
Factors No. of Patients Median OS (mo)
Univariate Analysis
p
Multivariate Analysis
HR (95% CI) p
Sex
Female 54 11.3
Male 62 12.8 0.641 1.31 (0.75–2.29) 0.336
Age (65 vs. 65)
65 52 14.1
65 64 9.6 0.341 0.97 (0.62–1.53) 0.899
Smoking
Non-/Light smoker 81 11.6
Heavy smoker 35 12.3 0.488 0.76 (0.42–1.38) 0.367
ECOG PS
0–1 99 13.8
2–4 17 1.4 0.001 5.88 (2.98—11.58) 0.001
EML4-ALK
Negative 77 10.3
Positive 39 14.7 0.009 0.53 (0.32–0.87) 0.011
EGFR TKI use
No 34 8.4
Yes 82 13.8 0.055 0.60 (0.35–1.00) 0.052
EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival.
TABLE 3. Characteristics and EML4-ALK Status of Lung
Adenocarcinoma Patients with Wild-Type EGFR
Variable Variant 1 Nonvariant 1 p
Total (N) 24 15
Age, median
(range)
68.8 (27.9—86.7) 57.8 (46.2—89.3) 0.279a
Sex
Female 10 (41.7%) 10 (66.7%) 0.129
Male 14 (58.3%) 5 (33.3%)
Smoking
Non-/light
smoker
15 (62.5%) 14 (93.3%) 0.057b
Heavy
smoker
9 (37.5%) 1 (6.7%)
ECOG PS
0–1 18 (75.0%) 14 (93.3%) 0.216b
2–4 6 (25.0%) 1 (6.7%)
a By Mann-Whitney U test.
b By Fisher’s exact test.
EGFR, epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology
Group performance status.
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significant difference in K-ras mutation between the heavy
smokers and non-/light smoker in this study. This was con-
sistent with prior studies that showed K-ras mutations in lung
adenocarcinoma were not significantly associated with any
specific clinical characteristics, including sex and smoking
status in Taiwan.29,32
Camidge et al.33 reported that, in comparison with
ALK-negative patients, ALK-positive patients had a signifi-
cantly longer progression-free survival on pemetrexed. How-
ever, no overall survival analysis was reported. In this study,
21 (53.8%) of the patients with EML4-ALK fusion genes and
29 (37.7%) of those without received pemetrexed treatment.
All 21 EML4-ALK positive patients received pemetrexed in
the third-, fourth-, or subsequent-line therapy. The longer
overall survival in patients with EML4-ALK may have re-
sulted from pemetrexed treatment or an indolent clinical
course, as previously reported.34 However, clinical trials are
necessary to understand the overall survival benefit of pem-
etrexed to lung adenocarcinoma patients with EML4-ALK
fusion genes.
In this study, 82 patients with EGFR TKI use had a
trend for improved overall survival. Most of the patients used
EGFR TKI in the first-line (60%) or second-line (24%)
treatment. The reason for the benefit of EGFR TKI in overall
survival is not clear and needs to be clarified in future studies.
The incidence of EML4-ALK is around 5% in unse-
lected populations of NSCLC patients.2,3,5,6,10,15 This study
enrolled all Asians, and the patients all had advanced-stage
lung adenocarcinoma with malignant pleural effusions and
wild-type EGFR. In the study by Shaw et al.,4 the frequency
of EML4-ALK was 33% among non-/light smokers without
EGFR mutations. In this study of all wild-type EGFR tumors,
the incidence of EML4-ALK was 35.8% for non-/light smok-
ers. These results are comparable.
Although prior studies has shown that patients harbor-
ing EML4-ALK were significantly younger than those without
EML4-ALK,2,4 this study did not show a similar result. This
may arise from the difference in patient enrollment. Samples
in prior studies mostly came from patients who underwent
tumor resection.2,3,5,9,15 However, in this study, all enrolled
patients were not eligible for surgery because of their ad-
vanced-stage disease of malignant pleural effusion. The age
of the patients in this study may be older than the prior
reports. It is also possible that RT-PCR method detects a
slightly different population from those ALK-positive patients
identified by FISH method.
RT-PCR is a rapid diagnostic method for detecting
EML4-ALK gene arrangement, as shown in prior studies
conducted in Asia.2,5,10,15,35 RT-PCR can provide sequence
data defining the types of different variants of EML4-ALK
fusion genes.26 It can be applied to samples with limited
number of cells, such as malignant pleural effusion, which are
not suitable for FISH studies. Although it is very sensitive in
detecting mutant transcript, RT-PCR must be multiplexed
and novel fusion partners other than EML4 may be missed.
For example, one patient in this study had tumor with FISH
positivity but negative in RT-PCR. In addition, the extracted
RNA from formalin-fixed paraffin-embedded tissue sample
may be degraded and not good enough for RT-PCR.26 FISH
was the standard test for enrollment of the patients in clinical
trials with crizotinib.13 But, both false-negative and false-
positive results have been observed.36 The commercially
available probe provided an advantage for research. How-
ever, in clinical practice, there were only small tissue samples
for the NSCLC patients with advanced stage. The residual
samples after clinical diagnostic use might be too small to
perform FISH. Recently, Paik et al.37 showed that EML4-ALK
rearrangement detection using immunohistochemical (IHC)
staining correlated well with FISH. IHC staining could be
applied broadly in routine biopsy tissue diagnosis in clinical
practice. However, prospective study is needed to compare
the usage of RT-PCR, FISH, and IHC.
This study evaluate the difference between patients
with variant 1 and those with nonvariant 1 EML4-ALK fusion
gene. For the 39 patients harboring EML4-ALK fusion genes,
there is no obvious difference in clinical characteristics in-
cluding gender, age, smoking history, and performance sta-
tus, between patients with variant1 and nonvariant 1 of the
EML4-ALK fusion gene. Survival outcome of the two groups
is also identical. Kwak et al.13 showed no difference in
crizotinib treatment response based on the EML4-ALK fusion
transcripts. The result of this study is consistent with the
study by Kwak et al. Because of the heterogeneous fusion
variants, enrolling more patients in a study may be needed to
identify the clinical characteristics of patients with different
variants of EML4-ALK fusion gene.13
Although crizotinib showed a high response rate and a
good safety profile among patients harboring the EML4-ALK
fusion gene,13 no patients in the present study took crizotinib.
Prospective clinical trials are necessary to clarify the impact
of crizotinib on overall survival.
There are limitations of the present cohort study. First,
we only collected patients with malignant pleural effusions,
resulting in selection bias. These results may not be general-
ized to all patients with stage IV NSCLC. However, most
patients with advanced stage of lung adenocarcinoma had
only small tissue samples. The tissue samples were mostly
used for clinical diagnosis, leaving limited residual samples
for molecular diagnosis. In addition, lung adenocarcinoma
patients frequently have malignant pleural effusions. Thora-
centesis is an easy way to collect malignant cells for molec-
ular studies in contrast to other invasive techniques used to
biopsy the primary tumor or its metastases in clinical prac-
tice.17 Second, we only validated the result of RT-PCR by
FISH in a limited number of patients. Even though we would
like to expand the study, because the availability of cancer
tissue samples in this cohort were limited, we were unable to
perform FISH in most patients.
In conclusion, EML4-ALK fusion gene is associated
with longer overall survival of lung adenocarcinoma patients
with wild-type EGFR mutations.
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